Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Applications of BCG-PSN (BCG-polysaccharide nuceic acid) in promoting proliferation of CIK cells (cytokine-induced killer cells) and in improving anti-tumor activity of CIK cells

A BCG polysaccharide nucleic acid and cell proliferation technology, which is applied in the fields of biomedicine and biotherapy to achieve the effect of improving the tumoricidal effect

Pending Publication Date: 2017-12-08
HUNAN SIQI BIOPHARM
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The proliferation and cytotoxic activity of CIK cells depend on the stimulation of a variety of exogenous cytokines, but it is still unclear which factor combination is the best, so studying how to further improve the proliferation and tumoricidal activity of CIK has become an anti-tumor adoptive A hot spot in immune cell biotherapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of BCG-PSN (BCG-polysaccharide nuceic acid) in promoting proliferation of CIK cells (cytokine-induced killer cells) and in improving anti-tumor activity of CIK cells
  • Applications of BCG-PSN (BCG-polysaccharide nuceic acid) in promoting proliferation of CIK cells (cytokine-induced killer cells) and in improving anti-tumor activity of CIK cells
  • Applications of BCG-PSN (BCG-polysaccharide nuceic acid) in promoting proliferation of CIK cells (cytokine-induced killer cells) and in improving anti-tumor activity of CIK cells

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0026] The preparation of BCG polysaccharide nucleic acid former powder is detailed as follows:

[0027] 1) Cultivation and harvest of BCG

[0028] 1. Bacterial culture: Dissolve the strains preserved in liquid cryogenic temperature (BCG strain D2PB302 for the preparation of BCG in China, China National Institute for the Control of Pharmaceutical and Biological Products) at room temperature, inoculate in potato Sutong culture medium, and culture continuously at 37°C for 14-20 days ; or after continuous cultivation at 37°C for 15 days, transfer to improved liquid Sutong medium, and continuous cultivation at 37°C for 14-20 days.

[0029] 2. Bacteria collection: When the bacteria grow to the logarithmic phase, check the culture bottles one by one, collect the bacteria film, add an appropriate amount of deionized distilled water to wash, press dry and weigh.

[0030] 2) Preparation of BCG polysaccharide nucleic acid

[0031] 1. Cell crushing and thermal phenol treatment: add the...

Embodiment 1

[0042] 1.1 Materials

[0043] Lymphocytes were isolated from peripheral blood of healthy volunteers. The SMMC-7721 liver cancer cell line was purchased from Shanghai Chinese Academy of Sciences and kept in our laboratory for a long time. Siqi Kang BCG polysaccharide nucleic acid injection (1ml / bottle) is produced by Hunan Siqi Biopharmaceutical Co., Ltd. Human blood lymphocyte separation medium was purchased from Jiahe Biotechnology. Blood collection needles, blood collection tubes, and normal saline were purchased from Changsha Fourth People's Hospital. Human CD3 monoclonal antibody was purchased from Beijing Tongliyuan Biotechnology Co., Ltd., and human interleukin (IL-2) was purchased from Jiangsu Jinsili Pharmaceutical Co., Ltd. DMEM culture medium, RPMI-1640, GT-T551 culture medium and fetal bovine serum are all products of Gibco, USA. Penicillin-streptomycin solution was produced by Biyuntian.

[0044] 1.2 Method

[0045] 1.2.1 CIK cell isolation and primary cultur...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to applications of BCG-PSN (BCG-polysaccharide nuceic acid). The BCG-PSN is capable of promoting proliferation of CIK cells (cytokine-induced killer cells) and capable of improving an anti-tumor effect of the CIK cells; the expression of related cytotoxic activity factors is also enhanced when the anti-tumor efficiency is improved; and the CIK cells, which accept induction culture of the BCG-PSN, are applicable to cell therapy of tumor diseases.

Description

technical field [0001] The invention belongs to the field of biomedicine and biotherapy, and specifically relates to the application of BCG polysaccharide nucleic acid extract in promoting the proliferation of CIK cells and enhancing the tumor-killing activity of CIK cells, as well as the application in preparing CIK cells. Background technique [0002] Malignant tumors seriously endanger human health. Currently, conventional surgery, radiotherapy and chemotherapy cannot completely eliminate tumor cells in the body. Adoptive immunotherapy has become an important adjuvant therapy for tumors due to its advantages of conforming to physiology, low toxicity and high efficiency. Among them, cytokine-induced killer cells (CIK cells) are a new type of anti-tumor cells discovered in recent years, based on CD3 + CD56 + A heterogeneous cell population dominated by T cells, with characteristics of both NK cells and T cells. In terms of function, on the one hand, CIK has the strong ant...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N5/0783
CPCC12N5/0646C12N2500/34C12N2500/40
Inventor 胡翔黄招琴谷陟欣颜冬兰朱艳
Owner HUNAN SIQI BIOPHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com